Loading…
All-treatment array of hepatocellular carcinoma from initial diagnosis to death: observation of cumulative treatments
Purpose In clinical practice, most patients with hepatocellular carcinoma require subsequent treatments for remaining, progressing, or recurring tumors. We investigated all-treatment array and outcomes in an HCC cohort from initial diagnosis to death. Methods We enrolled 1687 consecutive patients wi...
Saved in:
| Published in: | Journal of cancer research and clinical oncology 2017-11, Vol.143 (11), p.2327-2339 |
|---|---|
| Main Authors: | , , , , , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c470t-7481e839d897d75a825b729803f8d9411c6c457ccce7cd4d07184274003e96f53 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c470t-7481e839d897d75a825b729803f8d9411c6c457ccce7cd4d07184274003e96f53 |
| container_end_page | 2339 |
| container_issue | 11 |
| container_start_page | 2327 |
| container_title | Journal of cancer research and clinical oncology |
| container_volume | 143 |
| creator | Moon, Hae Choi, Ji Eun Lee, In Joon Kim, Tae Hyun Kim, Seong Hoon Ko, Young Hwan Kim, Hyun Boem Nam, Byung-Ho Park, Joong-Won |
| description | Purpose
In clinical practice, most patients with hepatocellular carcinoma require subsequent treatments for remaining, progressing, or recurring tumors. We investigated all-treatment array and outcomes in an HCC cohort from initial diagnosis to death.
Methods
We enrolled 1687 consecutive patients with HCC who underwent initial diagnosis and treatment at the National Cancer Center, Korea, from January 2004 to December 2009.
Results
In total, 1357 patients (80.4%) showed RPRTs during median 20.4-month follow-up. Initial transplantation resulted in the least rate (32.3%) of RPRTs. Median treatment frequency was 3.0 times (range 1–20) and 382 patients (27.3%) received treatments ≥6 times. The median treatment frequency was different based on four factors (
p
|
| doi_str_mv | 10.1007/s00432-017-2480-9 |
| format | article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5640756</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1923742617</sourcerecordid><originalsourceid>FETCH-LOGICAL-c470t-7481e839d897d75a825b729803f8d9411c6c457ccce7cd4d07184274003e96f53</originalsourceid><addsrcrecordid>eNp1kUFv2yAYhtG0aU3b_YBdKqRdenEHGAzsUCmKunZSpF3WMyIYJ0Q2pIAj5d8XK1nUVdoJwffwfHy8AHzF6A4jxL8nhGhNKoR5RahAlfwAZng6wXXNPoJZKeCKEdxcgMuUtqjsGSefwQURnFLG2QyM876vcrQ6D9ZnqGPUBxg6uLE7nYOxfT_2OkKjo3E-DBp2MQzQeZed7mHr9NqH5BLMAbZFsvkBwyrZuNfZBT-JzDgUQ3Z7C89t0jX41Ok-2S-n9Qo8_3z4s3iqlr8ffy3my8pQjnLFqcBW1LIVkrecaUHYihMpUN2JVlKMTWPKGMYYy01LW8SxoIRThGorm47VV-D-6N2Nq8G2pvSOule76AYdDypop_6teLdR67BXrKGIs6YIbk-CGF5Gm7IaXJp-RXsbxqSwJDWnpMG8oN_eodswRl_GKxTDpMQgaaHwkTIxpBRtd34MRmoKVR1DVSUrNYWqZLlz83aK842_KRaAHIFUSn5t45vW_7W-Am9ErsI</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1951221694</pqid></control><display><type>article</type><title>All-treatment array of hepatocellular carcinoma from initial diagnosis to death: observation of cumulative treatments</title><source>Springer Nature</source><creator>Moon, Hae ; Choi, Ji Eun ; Lee, In Joon ; Kim, Tae Hyun ; Kim, Seong Hoon ; Ko, Young Hwan ; Kim, Hyun Boem ; Nam, Byung-Ho ; Park, Joong-Won</creator><creatorcontrib>Moon, Hae ; Choi, Ji Eun ; Lee, In Joon ; Kim, Tae Hyun ; Kim, Seong Hoon ; Ko, Young Hwan ; Kim, Hyun Boem ; Nam, Byung-Ho ; Park, Joong-Won</creatorcontrib><description>Purpose
In clinical practice, most patients with hepatocellular carcinoma require subsequent treatments for remaining, progressing, or recurring tumors. We investigated all-treatment array and outcomes in an HCC cohort from initial diagnosis to death.
Methods
We enrolled 1687 consecutive patients with HCC who underwent initial diagnosis and treatment at the National Cancer Center, Korea, from January 2004 to December 2009.
Results
In total, 1357 patients (80.4%) showed RPRTs during median 20.4-month follow-up. Initial transplantation resulted in the least rate (32.3%) of RPRTs. Median treatment frequency was 3.0 times (range 1–20) and 382 patients (27.3%) received treatments ≥6 times. The median treatment frequency was different based on four factors (
p
< 0.05): age, tumor stage, tumor type and initial treatment modality. Patients with Barcelona Clinic Liver Cancer stage 0 received less frequent treatments. As the stage progressed from 0 to B, the median treatment frequency increased. Radiofrequency ablation as initial treatment was associated with the longest median treatment interval at 19.0 weeks, followed by resection at 14.1 weeks. The median treatment interval was significantly shorter as the stage progressed (
p
< 0.01). TACE was most frequently performed for RPRTs; the median number of subsequent TACE was 3 (range 1–19). Subsequent treatment array was very heterogeneous, and no certain pattern was found.
Conclusions
Our findings suggest that the survival outcome of patients with HCC is based on the results of cumulative multiple treatments rather than an initial treatment. It is time to consider prospective studies evaluating sequential treatment array of HCC.</description><identifier>ISSN: 0171-5216</identifier><identifier>EISSN: 1432-1335</identifier><identifier>DOI: 10.1007/s00432-017-2480-9</identifier><identifier>PMID: 28744575</identifier><language>eng</language><publisher>Berlin/Heidelberg: Springer Berlin Heidelberg</publisher><subject>Aged ; Cancer Research ; Cancer therapies ; Carcinoma, Hepatocellular - diagnosis ; Carcinoma, Hepatocellular - mortality ; Carcinoma, Hepatocellular - therapy ; Clinical outcomes ; Cohort analysis ; Combined Modality Therapy ; Diagnosis ; Female ; Follow-Up Studies ; Hematology ; Hepatocellular carcinoma ; Humans ; Internal Medicine ; Liver cancer ; Liver Neoplasms - diagnosis ; Liver Neoplasms - mortality ; Liver Neoplasms - therapy ; Male ; Medical treatment ; Medicine ; Medicine & Public Health ; Middle Aged ; Neoplasm Recurrence, Local - diagnosis ; Neoplasm Recurrence, Local - mortality ; Neoplasm Recurrence, Local - therapy ; Neoplasm Staging ; Oncology ; Original Article – Clinical Oncology ; Original – Clinical Oncology ; Republic of Korea ; Retrospective Studies ; Survival Rate ; Transplantation ; Treatment Outcome ; Tumors</subject><ispartof>Journal of cancer research and clinical oncology, 2017-11, Vol.143 (11), p.2327-2339</ispartof><rights>The Author(s) 2017</rights><rights>Journal of Cancer Research and Clinical Oncology is a copyright of Springer, 2017.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c470t-7481e839d897d75a825b729803f8d9411c6c457ccce7cd4d07184274003e96f53</citedby><cites>FETCH-LOGICAL-c470t-7481e839d897d75a825b729803f8d9411c6c457ccce7cd4d07184274003e96f53</cites><orcidid>0000-0001-9972-0494</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,780,784,885,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28744575$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Moon, Hae</creatorcontrib><creatorcontrib>Choi, Ji Eun</creatorcontrib><creatorcontrib>Lee, In Joon</creatorcontrib><creatorcontrib>Kim, Tae Hyun</creatorcontrib><creatorcontrib>Kim, Seong Hoon</creatorcontrib><creatorcontrib>Ko, Young Hwan</creatorcontrib><creatorcontrib>Kim, Hyun Boem</creatorcontrib><creatorcontrib>Nam, Byung-Ho</creatorcontrib><creatorcontrib>Park, Joong-Won</creatorcontrib><title>All-treatment array of hepatocellular carcinoma from initial diagnosis to death: observation of cumulative treatments</title><title>Journal of cancer research and clinical oncology</title><addtitle>J Cancer Res Clin Oncol</addtitle><addtitle>J Cancer Res Clin Oncol</addtitle><description>Purpose
In clinical practice, most patients with hepatocellular carcinoma require subsequent treatments for remaining, progressing, or recurring tumors. We investigated all-treatment array and outcomes in an HCC cohort from initial diagnosis to death.
Methods
We enrolled 1687 consecutive patients with HCC who underwent initial diagnosis and treatment at the National Cancer Center, Korea, from January 2004 to December 2009.
Results
In total, 1357 patients (80.4%) showed RPRTs during median 20.4-month follow-up. Initial transplantation resulted in the least rate (32.3%) of RPRTs. Median treatment frequency was 3.0 times (range 1–20) and 382 patients (27.3%) received treatments ≥6 times. The median treatment frequency was different based on four factors (
p
< 0.05): age, tumor stage, tumor type and initial treatment modality. Patients with Barcelona Clinic Liver Cancer stage 0 received less frequent treatments. As the stage progressed from 0 to B, the median treatment frequency increased. Radiofrequency ablation as initial treatment was associated with the longest median treatment interval at 19.0 weeks, followed by resection at 14.1 weeks. The median treatment interval was significantly shorter as the stage progressed (
p
< 0.01). TACE was most frequently performed for RPRTs; the median number of subsequent TACE was 3 (range 1–19). Subsequent treatment array was very heterogeneous, and no certain pattern was found.
Conclusions
Our findings suggest that the survival outcome of patients with HCC is based on the results of cumulative multiple treatments rather than an initial treatment. It is time to consider prospective studies evaluating sequential treatment array of HCC.</description><subject>Aged</subject><subject>Cancer Research</subject><subject>Cancer therapies</subject><subject>Carcinoma, Hepatocellular - diagnosis</subject><subject>Carcinoma, Hepatocellular - mortality</subject><subject>Carcinoma, Hepatocellular - therapy</subject><subject>Clinical outcomes</subject><subject>Cohort analysis</subject><subject>Combined Modality Therapy</subject><subject>Diagnosis</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>Hematology</subject><subject>Hepatocellular carcinoma</subject><subject>Humans</subject><subject>Internal Medicine</subject><subject>Liver cancer</subject><subject>Liver Neoplasms - diagnosis</subject><subject>Liver Neoplasms - mortality</subject><subject>Liver Neoplasms - therapy</subject><subject>Male</subject><subject>Medical treatment</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Middle Aged</subject><subject>Neoplasm Recurrence, Local - diagnosis</subject><subject>Neoplasm Recurrence, Local - mortality</subject><subject>Neoplasm Recurrence, Local - therapy</subject><subject>Neoplasm Staging</subject><subject>Oncology</subject><subject>Original Article – Clinical Oncology</subject><subject>Original – Clinical Oncology</subject><subject>Republic of Korea</subject><subject>Retrospective Studies</subject><subject>Survival Rate</subject><subject>Transplantation</subject><subject>Treatment Outcome</subject><subject>Tumors</subject><issn>0171-5216</issn><issn>1432-1335</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><recordid>eNp1kUFv2yAYhtG0aU3b_YBdKqRdenEHGAzsUCmKunZSpF3WMyIYJ0Q2pIAj5d8XK1nUVdoJwffwfHy8AHzF6A4jxL8nhGhNKoR5RahAlfwAZng6wXXNPoJZKeCKEdxcgMuUtqjsGSefwQURnFLG2QyM876vcrQ6D9ZnqGPUBxg6uLE7nYOxfT_2OkKjo3E-DBp2MQzQeZed7mHr9NqH5BLMAbZFsvkBwyrZuNfZBT-JzDgUQ3Z7C89t0jX41Ok-2S-n9Qo8_3z4s3iqlr8ffy3my8pQjnLFqcBW1LIVkrecaUHYihMpUN2JVlKMTWPKGMYYy01LW8SxoIRThGorm47VV-D-6N2Nq8G2pvSOule76AYdDypop_6teLdR67BXrKGIs6YIbk-CGF5Gm7IaXJp-RXsbxqSwJDWnpMG8oN_eodswRl_GKxTDpMQgaaHwkTIxpBRtd34MRmoKVR1DVSUrNYWqZLlz83aK842_KRaAHIFUSn5t45vW_7W-Am9ErsI</recordid><startdate>20171101</startdate><enddate>20171101</enddate><creator>Moon, Hae</creator><creator>Choi, Ji Eun</creator><creator>Lee, In Joon</creator><creator>Kim, Tae Hyun</creator><creator>Kim, Seong Hoon</creator><creator>Ko, Young Hwan</creator><creator>Kim, Hyun Boem</creator><creator>Nam, Byung-Ho</creator><creator>Park, Joong-Won</creator><general>Springer Berlin Heidelberg</general><general>Springer Nature B.V</general><scope>C6C</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7TO</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>M2O</scope><scope>MBDVC</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0001-9972-0494</orcidid></search><sort><creationdate>20171101</creationdate><title>All-treatment array of hepatocellular carcinoma from initial diagnosis to death: observation of cumulative treatments</title><author>Moon, Hae ; Choi, Ji Eun ; Lee, In Joon ; Kim, Tae Hyun ; Kim, Seong Hoon ; Ko, Young Hwan ; Kim, Hyun Boem ; Nam, Byung-Ho ; Park, Joong-Won</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c470t-7481e839d897d75a825b729803f8d9411c6c457ccce7cd4d07184274003e96f53</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Aged</topic><topic>Cancer Research</topic><topic>Cancer therapies</topic><topic>Carcinoma, Hepatocellular - diagnosis</topic><topic>Carcinoma, Hepatocellular - mortality</topic><topic>Carcinoma, Hepatocellular - therapy</topic><topic>Clinical outcomes</topic><topic>Cohort analysis</topic><topic>Combined Modality Therapy</topic><topic>Diagnosis</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>Hematology</topic><topic>Hepatocellular carcinoma</topic><topic>Humans</topic><topic>Internal Medicine</topic><topic>Liver cancer</topic><topic>Liver Neoplasms - diagnosis</topic><topic>Liver Neoplasms - mortality</topic><topic>Liver Neoplasms - therapy</topic><topic>Male</topic><topic>Medical treatment</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Middle Aged</topic><topic>Neoplasm Recurrence, Local - diagnosis</topic><topic>Neoplasm Recurrence, Local - mortality</topic><topic>Neoplasm Recurrence, Local - therapy</topic><topic>Neoplasm Staging</topic><topic>Oncology</topic><topic>Original Article – Clinical Oncology</topic><topic>Original – Clinical Oncology</topic><topic>Republic of Korea</topic><topic>Retrospective Studies</topic><topic>Survival Rate</topic><topic>Transplantation</topic><topic>Treatment Outcome</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Moon, Hae</creatorcontrib><creatorcontrib>Choi, Ji Eun</creatorcontrib><creatorcontrib>Lee, In Joon</creatorcontrib><creatorcontrib>Kim, Tae Hyun</creatorcontrib><creatorcontrib>Kim, Seong Hoon</creatorcontrib><creatorcontrib>Ko, Young Hwan</creatorcontrib><creatorcontrib>Kim, Hyun Boem</creatorcontrib><creatorcontrib>Nam, Byung-Ho</creatorcontrib><creatorcontrib>Park, Joong-Won</creatorcontrib><collection>Springer Nature OA Free Journals</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>ProQuest Health and Medical</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest research library</collection><collection>Research Library (Corporate)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Journal of cancer research and clinical oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Moon, Hae</au><au>Choi, Ji Eun</au><au>Lee, In Joon</au><au>Kim, Tae Hyun</au><au>Kim, Seong Hoon</au><au>Ko, Young Hwan</au><au>Kim, Hyun Boem</au><au>Nam, Byung-Ho</au><au>Park, Joong-Won</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>All-treatment array of hepatocellular carcinoma from initial diagnosis to death: observation of cumulative treatments</atitle><jtitle>Journal of cancer research and clinical oncology</jtitle><stitle>J Cancer Res Clin Oncol</stitle><addtitle>J Cancer Res Clin Oncol</addtitle><date>2017-11-01</date><risdate>2017</risdate><volume>143</volume><issue>11</issue><spage>2327</spage><epage>2339</epage><pages>2327-2339</pages><issn>0171-5216</issn><eissn>1432-1335</eissn><abstract>Purpose
In clinical practice, most patients with hepatocellular carcinoma require subsequent treatments for remaining, progressing, or recurring tumors. We investigated all-treatment array and outcomes in an HCC cohort from initial diagnosis to death.
Methods
We enrolled 1687 consecutive patients with HCC who underwent initial diagnosis and treatment at the National Cancer Center, Korea, from January 2004 to December 2009.
Results
In total, 1357 patients (80.4%) showed RPRTs during median 20.4-month follow-up. Initial transplantation resulted in the least rate (32.3%) of RPRTs. Median treatment frequency was 3.0 times (range 1–20) and 382 patients (27.3%) received treatments ≥6 times. The median treatment frequency was different based on four factors (
p
< 0.05): age, tumor stage, tumor type and initial treatment modality. Patients with Barcelona Clinic Liver Cancer stage 0 received less frequent treatments. As the stage progressed from 0 to B, the median treatment frequency increased. Radiofrequency ablation as initial treatment was associated with the longest median treatment interval at 19.0 weeks, followed by resection at 14.1 weeks. The median treatment interval was significantly shorter as the stage progressed (
p
< 0.01). TACE was most frequently performed for RPRTs; the median number of subsequent TACE was 3 (range 1–19). Subsequent treatment array was very heterogeneous, and no certain pattern was found.
Conclusions
Our findings suggest that the survival outcome of patients with HCC is based on the results of cumulative multiple treatments rather than an initial treatment. It is time to consider prospective studies evaluating sequential treatment array of HCC.</abstract><cop>Berlin/Heidelberg</cop><pub>Springer Berlin Heidelberg</pub><pmid>28744575</pmid><doi>10.1007/s00432-017-2480-9</doi><tpages>13</tpages><orcidid>https://orcid.org/0000-0001-9972-0494</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0171-5216 |
| ispartof | Journal of cancer research and clinical oncology, 2017-11, Vol.143 (11), p.2327-2339 |
| issn | 0171-5216 1432-1335 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5640756 |
| source | Springer Nature |
| subjects | Aged Cancer Research Cancer therapies Carcinoma, Hepatocellular - diagnosis Carcinoma, Hepatocellular - mortality Carcinoma, Hepatocellular - therapy Clinical outcomes Cohort analysis Combined Modality Therapy Diagnosis Female Follow-Up Studies Hematology Hepatocellular carcinoma Humans Internal Medicine Liver cancer Liver Neoplasms - diagnosis Liver Neoplasms - mortality Liver Neoplasms - therapy Male Medical treatment Medicine Medicine & Public Health Middle Aged Neoplasm Recurrence, Local - diagnosis Neoplasm Recurrence, Local - mortality Neoplasm Recurrence, Local - therapy Neoplasm Staging Oncology Original Article – Clinical Oncology Original – Clinical Oncology Republic of Korea Retrospective Studies Survival Rate Transplantation Treatment Outcome Tumors |
| title | All-treatment array of hepatocellular carcinoma from initial diagnosis to death: observation of cumulative treatments |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-27T08%3A08%3A22IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=All-treatment%20array%20of%20hepatocellular%20carcinoma%20from%20initial%20diagnosis%20to%20death:%20observation%20of%20cumulative%20treatments&rft.jtitle=Journal%20of%20cancer%20research%20and%20clinical%20oncology&rft.au=Moon,%20Hae&rft.date=2017-11-01&rft.volume=143&rft.issue=11&rft.spage=2327&rft.epage=2339&rft.pages=2327-2339&rft.issn=0171-5216&rft.eissn=1432-1335&rft_id=info:doi/10.1007/s00432-017-2480-9&rft_dat=%3Cproquest_pubme%3E1923742617%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c470t-7481e839d897d75a825b729803f8d9411c6c457ccce7cd4d07184274003e96f53%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1951221694&rft_id=info:pmid/28744575&rfr_iscdi=true |